These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12867140)

  • 1. New mode of intervention in sepsis treatment.
    Foubister V
    Drug Discov Today; 2003 Jul; 8(14):610-2. PubMed ID: 12867140
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating sepsis.
    Wenzel RP
    N Engl J Med; 2002 Sep; 347(13):966-7. PubMed ID: 12324551
    [No Abstract]   [Full Text] [Related]  

  • 3. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of sepsis.
    Mackenzie AF; Bartelink AK
    N Engl J Med; 2007 Mar; 356(11):1179; author reply 1181-2. PubMed ID: 17361493
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria for use of drotrecogin alfa.
    Jacobi J
    Am J Health Syst Pharm; 2004 Jan; 61(2):203-4; author reply 204-5. PubMed ID: 14750407
    [No Abstract]   [Full Text] [Related]  

  • 7. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of sepsis.
    Khurana A; Vinayek N
    N Engl J Med; 2007 Mar; 356(11):1178-9; author reply 1181-2. PubMed ID: 17366659
    [No Abstract]   [Full Text] [Related]  

  • 11. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 12. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 14. A new weapon against severe sepsis related to necrotizing fasciitis.
    Purnell D; Hazlett T; Alexander SL
    Dimens Crit Care Nurs; 2004; 23(1):18-23. PubMed ID: 14734896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C (Xigris): a drug in trouble.
    Vangerow B; Mignini MA
    Acta Anaesthesiol Scand; 2007 Feb; 51(2):261-2. PubMed ID: 17261152
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 20. Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
    Farmer JC
    Crit Care Med; 2005 Oct; 33(10):2428-31. PubMed ID: 16215411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.